|
| |
MTU391
|
|
|
Recommended
applications: RNA or
protein cancer tissue profiling using IHC or ISH; Antibody
characterization.
Description: 15 major types of cancer covering top 10 cancers
both in the East and West from 12 anatomic sites.
Most types have duplicates from different patients with
corresponding uninvolved tissues as controls. All the tissues were from
surgical resection. They were fixed in 10% neutral buffered formalin for
24 hours and processed using identical SOPs. Sections were picked onto
Superfrost Plus or APES coated Superfrost slides. They all have a
guaranteed six months' shelf-life at 4C from the date of shipment. Each
slide has >95% tissue core retention. |
| |
|
|
|
|
|
| |
|
|
Array
position |
Sex(es) |
Age(s) |
Anatomic site |
Histology |
Image |
|
A1,2,3 |
M,F,M |
46,63,72 |
Bladder |
A1 -
normal bladder, A2, 3 - transitional cell carcinoma |
|
|
A4,5,6 |
F,F,F |
28,46,48 |
Breast |
A4 -
normal breast, A5,6 - adenocarcinoma |
|
|
A7,8,B1 |
F,M,M |
47,49,77 |
GI-Stomach |
A7 -
normal stomach, A8,B1 - adenocarcinoma |
|
|
B2,3,4 |
M,F,M |
39,55,71 |
GI-Colonrectal |
B2 -
normal colon, B3 - colon carcinoma, B4 - rectal carcinoma |
|
|
B5,6,7 |
F,M,M |
33,60,68 |
Kidney |
B5 -
normal kidney cortex, B6,7 - clear cell carcinoma |
|
|
B8,C1,2 |
F,M,M |
45,33,38 |
Liver |
B8 -
normal, C1,2 - hepatocellular carcinoma |
|
|
C3,4,5 |
M,M,F |
38,65,67 |
Lung |
C3 -
normal lung, C4 - squamous cell carcinoma, C5 - adenocarcinoma |
|
|
C6,7,8 |
M,F,M |
35,27,59 |
Lymph
node |
C6 -
reactive, C7 - Hodgkin's, C8 - NHL-B |
|
|
D1,2,3 |
F,F,F |
25,38,47 |
Ovary |
D1 -
normal ovary, D2,3 -adenocarcinoma |
|
|
D4,5,6 |
M,M,F |
43,52,65 |
Pancreas |
D4 -
normal pancreas, D5,6 - adenocarcinoma |
|
|
D7,8,E1 |
M,M,M |
49,48,75 |
Prostate |
D7 -
normal prostate, D8,E1 - adenocarcinoma |
|
|
E2,3,4 |
F,F,M |
35,66,49 |
Skin |
E2 -
normal skin, E3 - squamous cell carcinoma, E4 - melanoma |
|
|
E5,6,7 |
F,F,F |
33,38,43 |
Uterus |
E5 - normal uterus, E6 - cervical
squamous cell carcinoma, E7 - endometrial adenocarcinoma |
|
|
|
+32 (0) 16
58 90 45 
+32 (0) 16
50 90 45
